Zalcitabine (2′-3′-dideoxycytidine, ddC), also called dideoxycytidine, is a
nucleoside analog reverse transcriptase inhibitor (NARTI) sold under the trade ...
Easy to read patient leaflet for zalcitabine. Includes indications, proper use,
special instructions, precautions, and possible side effects.
Jan 30, 2009 ... Learn about the prescription medication Hivid (Zalcitabine), drug uses, dosage,
side effects, drug interactions, warnings, reviews and patient ...
medication HIVID® (zalcitabine) Tablets will be discontinued by December 31,
2006. HIVID is one of the first nucleoside reverse transcriptase inhibitors (NRTIs),
ddC was also known as zalcitabine or dideoxycytidine. ddC was a nucleoside
analog reverse transcriptase inhibitor, or nuke. ddC was approved in 1992 as an
Jun 13, 2005 ... Zalcitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by
competing with the natural substrate dGTP and by its incorporation ...
Zalcitabine is a dideoxynucleoside compound in which the 3'-hydroxy group on
the sugar moiety has been replaced by a hydrogen. This modification prevents ...
The triphosphate form of zalcitabine inhibits HIV reverse transcriptase by
competing for incorporation into viral DNA as well as chain termination of the viral
ddC; 2',3'-Dideoxycytidine; Hivid; NSC 606170; Ro 24-2027/000. Zalcitabine is
an analog of pyrimidine derived from deoxycytidine with the replacement of the ...
zalcitabine (dideoxycytidine, ddC) Hivid. Pharmacologic classification:
nucleoside analogue. Therapeutic classification: antiviral. Pregnancy risk
category C ...